Evidence map›Paper›PMID 28152428›Full record

ArticleEuropean journal of medicinal chemistry2017

Exploration of DAPI analogues: Synthesis, antitrypanosomal activity, DNA binding and fluorescence properties.

Abdelbasset A Farahat, Arvind Kumar, Martial Say, Tanja Wenzler, Reto Brun, Ananya Paul, W David Wilson, David W Boykin

Open access · hybridAbstract read
In one paragraph

Article in European journal of medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. miR-21 Responsive Nanocarrier Targeting Ovarian Cancer Cells.Computational and structural biotechnology journal · 2024
    Article
  2. Article
  3. Escaping ESKAPE resistance:Royal Society open science · 2023
    Article
  4. Naphth[1,2-Molecules (Basel, Switzerland) · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Abdelbasset A FarahatDepartment of Chemistry, Georgia State University, Atlanta, GA 30303, United States; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt. Electronic address: afarahat@gsu.edu.
Arvind KumarDepartment of Chemistry, Georgia State University, Atlanta, GA 30303, United States.
Martial SayDepartment of Chemistry, Georgia State University, Atlanta, GA 30303, United States.
Tanja WenzlerSwiss Tropical and Public Health Institute, Basel 4002, Switzerland; University of Basel, Basel, 4003, Switzerland.
Reto BrunSwiss Tropical and Public Health Institute, Basel 4002, Switzerland; University of Basel, Basel, 4003, Switzerland.
Ananya PaulDepartment of Chemistry, Georgia State University, Atlanta, GA 30303, United States.
W David WilsonDepartment of Chemistry, Georgia State University, Atlanta, GA 30303, United States.
David W BoykinDepartment of Chemistry, Georgia State University, Atlanta, GA 30303, United States.
Georgia State University · USSwiss Tropical and Public Health Institute · CHMansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The DAPI structure has been modified by replacing the phenyl group with substituted phenyl or heteroaryl rings. Twelve amidines were synthesized and their DNA binding, fluorescence properties, in vitro and in vivo activities were evaluated. These compounds are shown to bind in the DNA minor groove with high affinity, and exhibit superior in vitro antitrypanosomal activity to that of DAPI. Six new diamidines (5b, 5c, 5d, 5e, 5f and 5j) exhibit superior in vivo activity to that of DAPI and four of these compounds provide 100% animal cure at a low dose of 4 × 5 mg/kg i.p. in T. b. rhodesiense infected mice. Generally, the fluorescence properties of the new analogues are inferior to that of DAPI with the exception of compound 5i which shows a moderate increase in efficacy while compound 5k is comparable to DAPI.

Indexed as

FluorescenceAnimalsCircular DichroismDisease Models, AnimalDNAIndolesMiceMolecular StructurePyridinesStructure-Activity RelationshipTrypanocidal AgentsTrypanosoma brucei rhodesienseTrypanosomiasis, African2-(4-amidino-3-methylphenyl)-1H-indole-5-amidine2-(4-amidino-3-methylphenyl)-1H-indole-6-amidine2-(5-amidinopyridine-2-yl)-1H-indole-6-amidineDAPIDNAIndolesPyridinesTrypanocidal AgentsAntitrypanosomal activityDAPIDiamidinesDNA minor groove bindersFluorescence propertiesPinner reactionStille coupling

Identifiers

PMID28152428
PMCPMC5341734
OpenAlexW2582864442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.